Case Report

Sphingomonas paucimobilis meningitis in a neonate
First case report

DR Rangaswamy¹, N Kamble¹, K Kavatagi²

DOI: https://doi.org/10.4038/sljid.v14i1.8607

Abstract

Neonatal meningitis caused by Sphingomonas paucimobilis, is an exceedingly rare occurrence, with only one documented case in the paediatric population as of 2019. Typically associated with nosocomial infections, we report a unique case of community-acquired S. paucimobilis meningitis in a neonate. A 25-day-old female neonate presented with poor feeding, lethargy, fever, and a maculopapular rash. A diagnostic workup revealed features suggestive of meningitis, with cerebrospinal fluid analysis confirming the presence of S. paucimobilis. The neonate responded positively to antibiotic therapy and recovered without complications.

Keywords: Sphingomonas paucimobilis, Gram Negative, Sepsis, NICU

Introduction

There is no documented instance of Sphingomonas paucimobilis causing neonatal meningitis in the present body of medical literature. In fact, in 2019 there has only been one occurrence documented of a toddler with S. paucimobilis meningitis. In neonates, S. paucimobilis has been reported to cause nosocomial infections, but in our case it appeared to be a community acquired infection.¹²

Case report

A 25-day old female baby born as term, small for gestational age, weighing 2.17 kg to a diabetic mother was admitted for a brief period of 24 hours to the Intensive Care Unit (ICU) in view of him having a transient tachypnoea and was later discharged on day 3 of life.

The baby was doing well until around three weeks post discharge following which the parents noted some abnormalities. The baby was brought to the emergency unit on her 25th day of life with complaints of poor feeding, lethargy, and fever for one day. At the time of presentation, the baby had a temperature of 100.4 °C with other vitals being stable, apart from relative

¹ Department of Paediatrics, Subbaiah Institute of Medical Sciences, Shimoga, Karnataka, India
²Department of Microbiology, Subbaiah Institute of Medical Sciences, Shimoga, Karnataka, India.
Address for correspondence: Dr Darshan Rajatadri Rangaswamy, Department of Paediatrics, Subbaiah Institute of Medical Sciences, Shimoga, Karnataka 577222, India; Email: Email-rajatadri93@gmail.com;
Telephone: +919481512233; https://orcid.org/0000-0001-8485-6073

Received 10 October 2023 and revised version accepted 16 January 2024. Published on 29.2.24

This an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

SLJID • www. sljol.info/index.php/SLJID • Vol. 14, No. 1; April 2024
The baby was lethargic and had a maculopapular rash over her face, chest, and extremities. Other system examinations were unremarkable. In view of the clinical features, the baby was subjected to screening for late onset neonatal sepsis and as the screen was positive with leukopenia of 8700 cells/mm³ (normal range: 9000-34000 cells/mm³) and elevated C Reactive Protein (CRP) of 1.3mg/L (normal: 0.1-1.0 mg/dL), blood culture and lumbar puncture were done, and the baby started on cefotaxime and amikacin as per our NICU protocol for late onset sepsis.

Analysis of cerebrospinal fluid (CSF) showed feature suggestive of meningitis: 25 polymorphs/mm³ (normal <10) microprotein -55mg/dL (normal: 10-50 mg/dL) and glucose-19 mg/dL (normal >34 mg/dL). One ml of CSF was sent to the microbiology laboratory in a BACTEC PF bottle and was incubated in BACT/ALERT 3D (BioMerieux) blood culture system. The CSF sample flagged positive after 72 hours and was subjected to Gram stain and subcultured on blood agar and MacConkey agar plates for 24 to 48 hrs. at 37 °C. Gram negative bacilli were seen on Gram stain and tiny non-lactose fermenting (NLF) colonies grew after incubation for 24 hours. After 48 hours, small, circular, smooth, convex NLF colonies were seen which were processed using VITEK 2 (BioMerieux) systems using the Gram negative (GN) card for identification and GNB oxidase positive AST card for susceptibility. The isolate was identified as Sphingomonas paucimobilis, susceptible to cefotaxime, ciprofloxacin, gentamicin, amikacin, and piperacillin-tazobactam.\(^3,4\) The blood culture taken at admission was sterile.

As the organism was sensitive to cefotaxime and amikacin, and there was clinical improvement, the same antibiotics were continued. A repeat lumbar puncture done on day four had no growth on culture and a 14 day course of antibiotics was therefore given. The baby had complete resolution of all the symptoms, had good activity and was haemodynamically stable at the time of discharge. The baby was taken home after completion of the antibiotic course in a sound condition. The baby was doing well when seen at the outpatient clinic after two weeks.

Timeline of the course of the infection is shown in Figure 1.
Discussion

The genus *Sphingomonas* was described by Yabuchi et al in 1900. *S. paucimobilis* is an occasional human pathogen, formerly known as CDC group IIk, biotype 1, then later named as *Pseudomonas paucimobilis* in 1977. *S. paucimobilis* is an oxidase and catalase positive Gram-negative rod with a single polar flagellum. It is motile when incubated at 18 to 22 °C and non-motile at 37 °C - hence it is named paucimobilis due to difficulty in demonstrating motility in the laboratory. On sheep blood agar it grows as deep yellow colonies with optimum growth at 30-37 °C. It does not grow on MacConkey agar (90% does not grow, 10% grow as NLFs). It utilises glucose, xylose, and sucrose oxidatively, is DNase and esculin hydrolysis positive, and urease and indole negative. It produces a zone A inhibition around vancomycin disk placed on a blood agar plate. It is susceptible to polymyxin B, which differentiates it from *Sphingobacterium*. 3,4

*S. paucimobilis* can cause both nosocomial and community-acquired infections. 7,9 Although described as causing a wide range of infections, there are only five cases of meningitis caused by *S. paucimobilis* in the published literature of which the first case of meningitis in the paediatric population was described in 2019. 5-9 There are no reports of meningitis caused by *S. paucimobilis* in neonates.

Given the initial presentation of our case, there was a significant likelihood of late-onset sepsis. A weak sensorium and fever indicated a possibility of meningitis. The microbiology team’s initial communication was of a Gram-negative bacteria suggestive of *S. paucimobilis*. As this organism is a rare cause of neonatal infection and was a possible contaminant, thorough scrutiny of the technique of sample collection, and the instruments used for sample collection and processing was done. However, there was no breach noted in the sterile chain.

After a brief hospital stay after birth, the infant spent the next three weeks at home before exhibiting the symptoms mentioned above. This lag/time at home increased the likelihood that the infection was acquired in the community. As reported recently, most of the *S. paucimobilis* infections in neonates are nosocomial in nature.

Conclusion

The case we described above is special since it is the first report of *S. paucimobilis* meningitis documented in a neonate. *S. paucimobilis* can cause significant sickness in neonates even though central nervous system infections are uncommon. Early diagnosis and the use of the appropriate antibiotics will enable satisfactory management in such cases.

Declarations

**Acknowledgement**: Acknowledgment: We would like to thank Dr Vinayaka G and Dr Amruthkishan Upadhyaya for their support.

**Conflicts of Interest**: There are no conflicts of interest.

**Funding**: No specific grant was given to this research by funding organisations in the public, private, or not-for-profit sectors.

**Ethics statement**: Ethics approval and informed consent for the submission and publishing of this case report, the patient guardian provided written informed consent. According to regional regulations, there was no need for ethical approval for this evaluation of the patient data.

**Authors’ contributions**: All the authors contributed equally to prepare this manuscript.
References


